Work

Faculty Opinions recommendation of Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Year: 2013

Type: peer-review

Abstract: Background-Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR.The expression of IGF-1R seems to be crucial for this effect.We investigated the safety and efficacy of the combination of the IGF-1R

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.717988709.793474324

Authors: Richard Gorlick, Jonathan Gill

Institution: Albert Einstein College of Medicine

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, Memorial Sloan-Kettering Cancer Center, National Cancer Institute